NDA 218585 · Lenz Therap
Vizz
Aceclidine Hydrochloride · Ophthalmic
NovelCDER novel approval, Jul 31, 2025: To treat presbyopia
Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 31, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 0 recruiting
FAERS reports
735
34 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 14, 2026.
VIZZ is indicated for the treatment of presbyopia in adults. VIZZ is a cholinergic agonist indicated for the treatment of presbyopia in adults ( 1 ).
Mechanism: Aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors located on smooth muscles. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VIZZ · ACECLIDINE HYDROCHLORIDE EQ 1.44% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aceclidine" as an intervention, any sponsor and status, largest first.
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of PresbyopiaPivotal-lookingCompleted
LENZ Therapeutics, IncAcademic, hospital or other
NCT05656027 · 469 participants · Start Dec 19, 2022 · Primary completion Dec 15, 2023
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Refractive Error; Eye Diseases and 1 more
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 25 sites in all
- Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia SubjectsPivotal-lookingCompleted
LENZ Therapeutics, IncAcademic, hospital or other
NCT05753189 · 362 participants · Start Feb 21, 2023 · Primary completion Feb 9, 2024
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Near Vision; Refractive Error and 1 more
Sites: Dothan, Alabama; Chandler, Arizona; Mesa, Arizona · 40 sites in all
- Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the PresbyopiaPivotal-lookingCompleted
Corxel PharmaceuticalsIndustry
NCT06045299 · 300 participants · Start Sep 27, 2023 · Primary completion Aug 19, 2024
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Near Vision; Miosis and 1 more
Sites: Wenzhou, China; Beijing, China; Changsha, China · 19 sites in all
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of PresbyopiaPivotal-lookingCompleted
LENZ Therapeutics, IncAcademic, hospital or other
NCT05728944 · 229 participants · Start Mar 6, 2023 · Primary completion Dec 14, 2023
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Near Vision; Refractive Error and 1 more
Sites: Dothan, Alabama; Scottsdale, Arizona; Glendale, California · 17 sites in all
LENZ Therapeutics, IncAcademic, hospital or other
NCT05294328 · 68 participants · Start May 5, 2022 · Primary completion Aug 22, 2022
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Refractive Errors; Eye Diseases
Sites: Glendale, California; Indianapolis, Indiana; Andover, Massachusetts · 5 sites in all
LENZ Therapeutics, IncAcademic, hospital or other
NCT05431543 · 59 participants · Start Aug 6, 2022 · Primary completion Dec 14, 2022
Drug: Aceclidine+Brimonidine combination ophthalmic solution; Aceclidine ophthalmic solution and 1 more · For: Presbyopia; Refractive Errors; Eye Diseases
Sites: Chandler, Arizona; Glendale, California; Andover, Massachusetts · 5 sites in all
LENZ Therapeutics, IncAcademic, hospital or other
NCT03201562 · 58 participants · Start Apr 30, 2017 · Primary completion May 20, 2018
Drug: Aceclidine+tropicamide combination; Aceclidine and 1 more · For: Presbyopia
Sites: Andover, Massachusetts
LENZ Therapeutics, IncAcademic, hospital or other
NCT05936489 · 30 participants · Start Jul 6, 2023 · Primary completion Oct 3, 2023
Drug: Aceclidine + Brimonidine; Aceclidine · For: Eye Diseases; Presbyopia; Refractive Errors and 3 more
Sites: Newport Beach, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ocular hyperaemia310
- visual impairment248
- instillation site irritation240
- headache167
- vision blurred102
- drug ineffective100
- drug effect less than expected76
- vitreous floaters43
- nausea34
- off label use33
- dizziness27
- condition aggravated17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2021 | 1 |
| 2025 | 173 |
| 2026 | 560 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Timolol and aceclidine. A clinical study of interaction in the eye.
van der Pol BA, Wattel E · Acta Ophthalmol (Copenh) 1985 · Clinical Trial, Comparative Study
- Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma.
Romano JH · Br J Ophthalmol 1970 · Clinical Trial, Comparative Study
- Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial.
Randazzo A, Nizzola F, Rossetti L, et al. · J Cataract Refract Surg 2005 · Randomized Controlled Trial
Sponsor: Lenz Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.